All News
Filter News
Found 808,679 articles
-
PeriGen to Demonstrate First Ever Artificial Intelligence-Based Fetal and Maternal Early Warning Solution at AWHONN
6/19/2018
Automated platform works alongside existing perinatal system to help labor and delivery clinicians quickly, easily and consistently identify patients developing worsening conditions
-
Microbiotica Collaborates with University of Adelaide to Develop a Novel Microbial Therapy for Ulcerative Colitis
6/19/2018
Microbiotica, today announced that it has entered into an agreement with University of Adelaide as part of its programme to develop a defined bacterial product for ulcerative colitis (UC).
-
Cambium Enrolls First Patient in Phase I/II Study to Evaluate Platelet Lysate Biologic for Graft-vs.-Host Disease Dry Eye
6/19/2018
Cambium Medical Technologies (“Cambium”), a clinical stage company, announced today first patient enrollment for its Elate Ocular™.
-
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
6/19/2018
Novartis announced today that the U.S. Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab) significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).1
-
GenomeDx Biosciences and Pathnostics Launch Enhanced Version of Guidance Tests
6/19/2018
GenomeDx Biosciences and Pathnostics today announced the launch of the next generation Guidance testing for patients suffering from simple cystitis.
-
Leading BioSciences Reports Positive Interim Results from Phase 2 Trial of LB1148 in Patients Undergoing Major Surgery
6/19/2018
Leading BioSciences today reported positive interim data from the company’s ongoing Phase 2 clinical trial of its lead drug candidate, LB1148.
-
Anika Therapeutics Announces Top-Line Results from CINGAL 16-02 Clinical Trial in Knee Osteoarthritis
6/19/2018
Anika Therapeutics, a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology platform, today announced results from its...
-
Enamine and TBD Biodiscovery Collaborate to Provide GMP-Based Services
6/19/2018
Enamine and TBD Biodiscovery collaborate to provide GMP-based services.
-
Johnson & Johnson to Host Investor Conference Call on 2018 Second-Quarter Results
6/19/2018
Johnson & Johnson will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 17, to review second-quarter results.
-
The Stepping Stones Group Appoints Timothy R. Murphy as Chief Executive Officer
6/19/2018
The Stepping Stones Group announced that Timothy R. Murphy (Tim) is joining The Stepping Stones Group as Chief Executive Officer effective June 18th.
-
Shrader and Associates LLP: Ploetz Lawyers Respond to NCAA
6/19/2018
The following is a statement from Justin Shrader, Shrader and Associates LLP:
-
Minister of Health Ginette Petitpas Taylor announces intent to severely restrict marketing of opioids
6/19/2018
Today, the Public Health Agency of Canada, on behalf of the federal, provincial and territorial Special Advisory Committee on the Epidemic of Opioid Overdoses, released preliminary data on opioid-related deaths for all of 2017.
-
ITM: FDA Acceptance of IND to Advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S.
6/19/2018
Isotopen Technologien München AG announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug Application (IND) to advance its innovative radiopharmaceutical Solucin® (n.c.a. 177Lu-Edotreotide), into a phase III clinical trial in the U.S..
-
Concordia International Corp. Announces Approval of its CBCA Plan of Arrangement by its Shareholders and Debtholders
6/19/2018
Concordia International Corp. announced that at the meetings of holders of certain secured debt of Concordia approved the previously announced recapitalization transaction (the "Recapitalization Transaction") to be implemented pursuant to a plan of arrangement under the Canada Business Corporations Act (the "CBCA").
-
Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes
6/19/2018
Oxitec, Ltd. announced it is entering into a cooperative agreement with the Bill & Melinda Gates Foundation ("BMGF") to develop a new strain of Oxitec's self-limiting Friendly(TM) Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere.
-
In Her Shoes 2018: New Profile Added to Raise Funds for Separated Immigrant Families
6/19/2018
Maternal malnutrition awareness campaign asks participants to adopt the diet of a woman in a crisis setting
-
Luye Pharma Bolsters Its Global Analgesics Portfolio with China Class 1.1 New Compound LY03012 to Start Phase I Clinical Trials
6/19/2018
Luye Pharma Group announced that clinical applications of the company's new compound candidate have been formally accepted by the China Food and Drug Administration.
-
Maurice A. Deane School of Law at Hofstra University Forms First Medical-Legal Partnership with Northwell Health
6/19/2018
The Maurice A. Deane School of Law at Hofstra University is partnering with Northwell Health to provide legal services for patients facing issues that contribute to poor health, such as denial of health care coverage, social services or benefits, immigration and disability benefits.
-
Children's Hospital of Philadelphia Announces New Hospital
6/19/2018
163-Year-Old Pediatric Icon Details Plans to Increase Range of Care in Region
-
Consumer Watchdog: Deadline Approaching for Current and Former Health Net Members in California To Submit Claims for Out-of-Network Medical Visits in 2014
6/19/2018
Claim Forms Due June 25, 2018